Posted by Michael Wonder on 17 Oct 2024
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
17 October 2024 - For the first time, NICE has recommended a targeted treatment option for ALK positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.
Alectinib hydrochloride, also known as Alecensa, is recommended as an option for the treatment of stage 1B (tumours 4cm or larger) to 3A ALK positive non-small-cell lung cancer after surgery to completely remove the tumour.
NICE has also today recommended pembrolizumab with chemotherapy before surgery (neo-adjuvant) then pembrolizumab alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer.
